Vectura Group’s (VEC) Buy Rating Reiterated at Morgan Stanley
Vectura Group (LON:VEC)‘s stock had its “buy” rating restated by investment analysts at Morgan Stanley in a note issued to investors on Friday, Digital Look reports. They presently have a GBX 160 ($2.09) price objective on the stock. Morgan Stanley’s price objective would suggest a potential upside of 99.88% from the company’s previous close.
Several other research analysts have also commented on the company. Peel Hunt reissued a “hold” rating on shares of Vectura Group in a research report on Friday. Shore Capital reissued a “hold” rating on shares of Vectura Group in a research report on Friday. Numis Securities reissued a “buy” rating on shares of Vectura Group in a research report on Friday. Finally, JPMorgan Chase & Co. cut their price objective on Vectura Group from GBX 110 ($1.44) to GBX 100 ($1.31) and set an “overweight” rating on the stock in a research report on Wednesday, April 3rd. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Vectura Group has a consensus rating of “Buy” and a consensus price target of GBX 122.86 ($1.61).
LON:VEC traded up GBX 1.55 ($0.02) during mid-day trading on Friday, hitting GBX 80.05 ($1.05). The company had a trading volume of 409,711 shares, compared to its average volume of 4,610,000. The company has a debt-to-equity ratio of 0.81, a current ratio of 2.35 and a quick ratio of 1.90. Vectura Group has a 1 year low of GBX 65.85 ($0.86) and a 1 year high of GBX 90.15 ($1.18). The firm has a market capitalization of $525.94 million and a PE ratio of -6.06.
Vectura Group plc engages in the design, development, and supply of pharmaceutical products for the treatment of airways-related diseases worldwide. The company's in-market products include Seebri Breezhaler and Neohaler, a DPI device and bronchodilator; AirFluSal Forspiro for the treatment of asthma and chronic obstructive pulmonary disease (COPD); Breelib for the treatment of pulmonary arterial hypertension; Relvar Ellipta/Breo Ellipta that is used in treating asthma and COPD; and Incruse Ellipta and Anoro Ellipta for the treatment of COPD.
Further Reading: What are earnings reports?
Receive News & Ratings for Vectura Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group and related companies with MarketBeat.com's FREE daily email newsletter.